Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy

被引：41

作者：

Ina, Kenji ^{[1
]}

Furuta, Ryuichi ^{[1
]}

Kataoka, Takae ^{[2
]}

Kayukawa, Satoshi ^{[2
]}

Yoshida, Takashi ^{[2
]}

Miwa, Takaya ^{[3
]}

Yamamura, Yoshitaka ^{[3
]}

Takeuchi, Yuuki ^{[3
]}

机构：

[1] Nagoya Mem Hosp, Dept Med Oncol, Nagoya, Aichi 4688520, Japan

[2] Nagoya Mem Hosp, Dept Clin Oncol, Nagoya, Aichi 4688520, Japan

[3] Nagoya Mem Hosp, Dept Surg, Nagoya, Aichi 4688520, Japan

来源：

WORLD JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 2卷 / 10期

关键词：

Gastric cancer; Lentinan; S-1-based chemo-therapy;

D O I：

10.5306/wjco.v2.i10.339

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

AIM: To examine whether administration of lentinan, purified beta-1, 3-glucan, can prolong survival in advanced gastric cancer patients receiving S-1-based chemotherapy. METHODS: Since 2004, 78 patients with metastatic or recurrent gastric cancer have received S-1-based chemotherapy as first-line treatment. Survival, side effects, and the ratio of granulocytes/lymphocytes (G/L ratio) were compared between 2 groups of patients who received chemo-immunotherapy using lentinan and chemotherapy alone. RESULTS: Median overall survival was significantly longer in the former group than in the latter group [689 d (95% CI: 431-2339 d) vs 565 d (95% CI: 323-662 d), P = 0.0406]. In addition, the G/L ratio in patients who received lentinan was maintained around or below 2, which was significantly lower than that in patients who received chemotherapy alone (P < 0.001). CONCLUSION: Chemo-immunotherapy with lentinan offers a significant advantage over S-1-based chemotherapy alone in terms of survival in patients with advanced gastric cancer. (C) 2011 Baishideng. All rights reserved.

引用

页码：339 / 343

页数：5

共 29 条

[1]

Immune recognition -: A new receptor for β-glucans [J].

Brown, GD ;

Gordon, S .

NATURE, 2001, 413 (6851) :36-37

[2]

INHIBITION OF MOUSE SARCOMA 180 BY POLYSACCHARIDES FROM LENTINUS EDODES (BERK) SING [J].

CHICHARA, G ;

MAEDA, Y ;

HAMURO, J ;

SASAKI, T ;

FUKUOKA, F .

NATURE, 1969, 222 (5194) :687-&

[3]

HAMURO J, 1978, CANCER RES, V38, P3080

[4]

Gastric cancer [J].

Hohenberger, P ;

Gretschel, S .

LANCET, 2003, 362 (9380) :305-315

[5]

Pathological complete response induced by the combination therapy of S-1 and 24-h infusion of cisplatin in two cases initially diagnosed as inoperable advanced gastric cancer [J].

Ina, Kenji ;

Kataoka, Takae ;

Takeuchi, Yuuki ;

Fukuoka, Tomoki ;

Miwa, Takaya ;

Nishio, Tomoko ;

Furuta, Ryuichi ;

Masaki, Ayako ;

Mori, Fumiko ;

Kayukawa, Satoshi ;

Nagao, Seiji ;

Ando, Takafumi ;

Goto, Hidemi .

ONCOLOGY REPORTS, 2008, 20 (02) :259-264

[6]

Ina Kenji, 2009, Gan To Kagaku Ryoho, V36, P979

[7]

Iwase H, 2005, ANTICANCER RES, V25, P1297

[8]

A Phase II Multi-Center Study of Triple Therapy with Paclitaxel, S-1 and Cisplatin in Patients with Advanced Gastric Cancer [J].

Iwase, H. ;

Shimada, M. ;

Tsuzuki, T. ;

Ina, K. ;

Sugihara, M. ;

Haruta, J. ;

Shinoda, M. ;

Kumada, T. ;

Goto, H. .

ONCOLOGY, 2011, 80 (1-2) :76-83

[9]

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial [J].

Koizumi, Wasaburo ;

Narahara, Hiroyuki ;

Hara, Takuo ;

Takagane, Akinori ;

Akiya, Toshikazu ;

Takagi, Masakazu ;

Miyashita, Kosei ;

Nishizaki, Takashi ;

Kobayashi, Osamu ;

Takiyama, Wataru ;

Toh, Yasushi ;

Nagaie, Takashi ;

Takagi, Seiichi ;

Yamamura, Yoshitaka ;

Yanaoka, Kimihiko ;

Orita, Hiroyuki ;

Takeuchi, Masahiro .

LANCET ONCOLOGY, 2008, 9 (03) :215-221

[10]

Kubota E, 2009, HEPATO-GASTROENTEROL, V56, P106

← 1 2 3 →